Skip to main content
. 2024 Sep 5;18(9):e0012486. doi: 10.1371/journal.pntd.0012486

Fig 1. Analytical framework for using a qualitative G6PD test to guide PQ treatment decisions.

Fig 1

[1] Is there direct evidence that using a qualitative G6PD test reduces P. vivax infections in the 6 months following treatment? [2] What is the prevalence of G6PD activity <30% of adjusted-male median in the target group? [3] Can G6PD tests be used to accurately classify G6PD activity? [4] Does treatment with PQ result in fewer future P. vivax infections? [5] What are the consequences of not having access to near patient G6PD testing? [6] Does treatment result in adverse effects, specifically severe haemolysis?